| Literature DB >> 32215327 |
Oyebamiji Abel Kolawole1,2, Fadare Olatomide A3, Semire Banjo2.
Abstract
Gastric cancer as a dreaded disease which occurs in the digestive system of human being remain a threat to the medical world. Bioactivity of series of designed and synthesized molecular compounds containing triazole and pyrimidine moieties were subjected to quantum chemical calculations using B3LYP/6-31+G∗. The calculated molecular descriptors such as the EHOMO (eV), ELUMO (eV), band gap (eV), chemical hardness (η), global nucleophilicity, dipole moment (Debye), chemical potential, log P, molecular weight (amu) and Ovality. The descriptors that describe anti-gastric cancer activity of the studied compounds were used for QSAR analysis using SPSS and Gretl software packages for multiple linear regression (MLR), XLSTAT for partial least square (PLS) and MATLAB for artificial neural network (ANN). The methods (MLR, PLS, and ANN) were predictive. Nevertheless, ANN performed better than MLR and PLS. More so, molecular docking study was executed on the studied compounds and gastric cancer cell line (PDB ID:4oum); the docking studies showed that 2-(1-(2-(3-benzyl-5-(benzylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)hydrazono)ethyl)phenol (A22) having the lowest binding affinity (-8.40 kcal/mol); this was correlated to the observed inhibitory activity of the compound against gastric cancer. Thus, it showed better inhibition than other studied compounds. The amino acid residues that were involved in stabilizing A22 in the active site of the 4oum are: VAL-9, ALA-10, THR-49, ASN-48, PRO-47 and TYR-46. Also, a good relationship was observed between the calculated binding affinity and the observed inhibition concentration (IC50).Entities:
Keywords: 1, 2, 3-triazolo[4, 5-d]pyrimidine hybrids; DFT; Molecular docking; Pharmaceutical chemistry; QSAR; Theoretical chemistry
Year: 2020 PMID: 32215327 PMCID: PMC7090349 DOI: 10.1016/j.heliyon.2020.e03561
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1The schematic structures of 1,2,3-triazolo[4, 5-d]pyrimidine analogues.
Pearson's correlation matrix for calculated parameters.
| MGC803 | EHOMO | ELUMO | PSA | HBA | CON/n | N4 | N5 | NOR | NOH | VIF | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MGC803 | 1.000 | - | |||||||||
| HOMO | 0.296 | 1.000 | 1.548 | ||||||||
| LUMO | 0.430 | 0.223 | 1.000 | 3.462 | |||||||
| PSA | -0.139 | -0.036 | 0.336 | 1.000 | 2.281 | ||||||
| HBA | 0.167 | 0.253 | 0.226 | 0.543 | 1.000 | 8.506 | |||||
| CON/n | -0.240 | -0.162 | -0.136 | 0.039 | -0.332 | 1.000 | 3.182 | ||||
| N4 | -0.083 | -0.131 | -0.096 | 0.093 | -0401 | 0.203 | 1.000 | 1.641 | |||
| N5 | 0.252 | -0.101 | 0.494 | 0.080 | -0.299 | 0.608 | 0.008 | 1.000 | 4.980 | ||
| NOR | 0.088 | 0.022 | 0.190 | 0.495 | 0.867 | -0.170 | -0.364 | -0.155 | 1.000 | 5.372 | |
| NOH | -0.414 | 0.180 | -0.116 | 0.066 | 0.035 | 0.020 | -0.006 | -0.025 | -0.070 | 1.000 | 1.139 |
Calculate descriptors from 1,2,3-triazolo[4,5-d]pyrimidine derivatives.
| HOMO | LUMO | PSA | HBA | CON/n | N4 | N5 | NOR | NOH | MGC-803 | |
|---|---|---|---|---|---|---|---|---|---|---|
| A1 | -6.68 | -2.74 | 53.122 | 7 | -0.189 | 0.011 | 0.28 | 9 | 4 | 10.91 |
| A2 | -6.44 | -2.55 | 81.433 | 10 | -0.165 | -0.078 | 0.261 | 11 | 4 | 9.41 |
| A3 | -5.88 | -2.41 | 107.577 | 10 | -0.211 | 0.07 | 0.238 | 11 | 4 | 10.05 |
| A4 | -5.66 | -2.47 | 60.796 | 8 | -0.178 | -0.054 | 0.264 | 9 | 4 | 13.14 |
| A5 | -5.92 | -2.47 | 69.208 | 8 | -0.252 | 0.126 | 0.175 | 9 | 5 | 7.41 |
| A6 | -6.13 | -2.67 | 72.457 | 8 | -0.219 | 0.119 | 0.228 | 9 | 5 | 3.71 |
| A7 | -6.44 | -2.39 | 76.777 | 8 | -0.209 | 0.098 | 0.263 | 9 | 4 | 2.31 |
| A8 | -6.36 | -2.42 | 78.887 | 8 | -0.23 | 0.096 | 0.239 | 9 | 4 | 16.72 |
| A9 | -6.54 | -2.49 | 59.086 | 7 | -0.227 | 0.104 | 0.237 | 9 | 4 | 6.02 |
| A10 | -6.62 | -2.6 | 73.549 | 8 | -0.243 | 0.069 | 0.239 | 10 | 4 | 6.50 |
| A11 | -6.45 | -2.41 | 76.777 | 8 | -0.221 | -0.004 | 0.278 | 10 | 4 | 7.10 |
| A12 | -6.47 | -2.43 | 76.777 | 8 | -0.222 | 0.005 | 0.286 | 10 | 4 | 11.28 |
| A13 | -6.42 | -2.37 | 76.777 | 8 | -0.222 | 0.072 | 0.277 | 10 | 4 | 10.98 |
| A14 | -6.57 | -2.59 | 81.072 | 9 | -0.244 | 0.072 | 0.172 | 10 | 4 | 4.76 |
| A15 | -6.63 | -2.59 | 73.634 | 9 | -0.238 | 0.041 | 0.209 | 10 | 4 | 16.38 |
| A16 | -6.42 | -2.36 | 96.667 | 9 | -0.215 | 0.133 | 0.265 | 10 | 4 | 7.68 |
| A17 | -6.49 | -2.65 | 81.433 | 10 | -0.169 | -0.007 | 0.241 | 13 | 4 | 4.67 |
| A18 | -6.13 | -2.71 | 72.457 | 8 | -0.218 | 0.121 | 0.209 | 9 | 5 | 10.51 |
| A19 | -5.67 | -2.55 | 60.796 | 8 | -0.178 | 0.028 | 0.25 | 9 | 4 | 7.62 |
| A20 | -6.65 | -2.63 | 73.398 | 8 | -0.24 | -0.008 | 0.239 | 9 | 4 | 3.82 |
| A21 | -6.45 | -2.57 | 81.433 | 10 | -0.164 | -0.079 | 0.253 | 11 | 5 | 1.32 |
| A22 | -6.44 | -2.38 | 76.772 | 8 | -0.215 | -0.046 | 0.264 | 9 | 5 | 0.85 |
| A23 | -5.99 | -2.31 | 66.518 | 9 | -0.23 | -0.02 | 0.408 | 10 | 4 | 31.20 |
| A24 | -6.19 | -2.29 | 75.701 | 10 | -0.292 | 0.156 | 0.102 | 11 | 4 | 11.55 |
| A25 | -6.19 | -2.33 | 73.258 | 10 | -0.31 | -0.137 | 0.129 | 11 | 4 | 16.37 |
| A26 | -6.05 | -2.28 | 67.971 | 9 | -0.27 | -0.084 | 0.267 | 10 | 4 | 17.42 |
| A27 | -6.17 | -2.21 | 74.31 | 10 | -0.285 | -0.118 | 0.235 | 11 | 4 | 19.22 |
| A28 | -5.82 | -2.25 | 86.393 | 11 | -0.317 | -0.136 | 0.16 | 12 | 5 | 9.21 |
| A29 | -6.22 | -2.82 | 66.81 | 9 | -0.285 | 0.049 | 0.019 | 10 | 4 | 10.42 |
| A30 | -6.21 | -2.65 | 70.955 | 9 | -0.254 | 0.1 | 0.088 | 10 | 3 | 16.65 |
| A31 | -6.24 | -2.89 | 66.386 | 9 | -0.293 | -0.252 | 0.053 | 10 | 4 | 2.37 |
| A32 | -6.23 | -3.02 | 67.893 | 9 | -0.256 | 0.087 | 0.061 | 10 | 5 | 2.88 |
Figure 2The calculated predicted IC50 against the observed IC50 using MLR via OLS.
Figure 3Graphical representation of the coefficient against the independent variables.
Stepwise regression result for anti-gastric cancer activity.
| Obs. IC50 | OLS-MLR | Residual | PLS-MLR | Residual | ANN-MLR | Residual | |
|---|---|---|---|---|---|---|---|
| A1 | 10.91 | 9.29 | 1.62 | 9.287 | 1.623 | 10.885 | 0.02 |
| A2 | 9.41 | 9.76 | -0.35 | 9.766 | -0.356 | 9.382 | 0.02 |
| A3 | 10.05 | 6.07 | 3.98 | 6.064 | 3.986 | 10.046 | 0.00 |
| A4 | 13.14 | 10.23 | 2.91 | 10.232 | 2.908 | 13.112 | 0.02 |
| A5 | 7.41 | 5.69 | 1.72 | 5.693 | 1.717 | 7.391 | 0.01 |
| A6 | 3.71 | 5.31 | -1.6 | 5.313 | -1.603 | 3.707 | 0.00 |
| A7 | 2.31 | 10.49 | -8.18 | 10.488 | -8.178 | 2.301 | 0.00 |
| A8 | 16.72 | 9.76 | 6.96 | 9.763 | 6.957 | 16.703 | 0.01 |
| A9 | 6.02 | 9.46 | -3.44 | 9.459 | -3.439 | 5.991 | 0.02 |
| A10 | 6.5 | 9.27 | -2.77 | 9.274 | -2.774 | 6.471 | 0.02 |
| A11 | 7.1 | 7.33 | -0.23 | 7.329 | -0.229 | 7.095 | 0.00 |
| A12 | 11.28 | 8.15 | 3.13 | 8.153 | 3.127 | 11.25 | 0.02 |
| A13 | 10.98 | 9.08 | 1.9 | 9.081 | 1.899 | 10.95 | 0.02 |
| A14 | 4.76 | 9.35 | -4.59 | 9.355 | -4.595 | 4.74 | 0.01 |
| A15 | 16.38 | 13.28 | 3.1 | 13.281 | 3.099 | 16.35 | 0.02 |
| A16 | 7.68 | 9.19 | -1.51 | 9.190 | -1.510 | 7.67 | 0.00 |
| A17 | 4.67 | 4.77 | -0.1 | 4.774 | -0.104 | 4.65 | 0.01 |
| A18 | 10.51 | 4.00 | 6.51 | 4.000 | 6.510 | 10.48 | 0.02 |
| A19 | 7.62 | 11.17 | -3.55 | 11.166 | -3.546 | 7.59 | 0.02 |
| A20 | 3.82 | 10.12 | -6.3 | 10.119 | -6.299 | 3.79 | 0.02 |
| A21 | 1.32 | 3.5 | -2.18 | 3.501 | -2.181 | 1.3 | 0.01 |
| A22 | 0.85 | 2.12 | -1.27 | 2.118 | -1.268 | 0.84 | 0.00 |
| A23 | 31.2 | 27.15 | 4.05 | 27.152 | 4.048 | 31.17 | 0.02 |
| A24 | 11.55 | 16.61 | -5.06 | 16.605 | -5.055 | 11.52 | 0.02 |
| A25 | 16.37 | 14.02 | 2.35 | 14.020 | 2.350 | 16.34 | 0.02 |
| A26 | 17.42 | 18.89 | -1.47 | 18.884 | -1.464 | 17.39 | 0.02 |
| A27 | 19.22 | 19.22 | 0.00 | 19.219 | 0.001 | 19.19 | 0.02 |
| A28 | 9.21 | 10.74 | -1.53 | 10.736 | -1.526 | 9.19 | 0.01 |
| A29 | 10.42 | 6.84 | 3.58 | 6.842 | 3.578 | 10.4 | 0.01 |
| A30 | 16.65 | 14.33 | 2.32 | 14.334 | 2.316 | 16.64 | 0.00 |
| A31 | 2.37 | 3.03 | -0.66 | 3.032 | -0.662 | 2.34 | 0.02 |
| C32 | 2.88 | 2.21 | 0.67 | 2.213 | 0.667 | 2.87 | 0.00 |
Figure 4The residuals against observed IC50.
Figure 5The calculated predicted IC50 against the observed IC50 using multiple non-linear regression method.
Figure 6Graphical illustration of predicted and observed bioactivity using artificial neural network method.
Figure 7Correlation between Binding affinity and Observed IC50.
Figure 8Molecular binding interaction between A17, A18, A20, A21, and A32 with 4oum.
Interactions between ligands and 4oum receptor.
| Comp | Scoring | K | Hydrogen Bonds | Amino Acid Residues |
|---|---|---|---|---|
| A1 | -7.2 | 1.90913 × 105 | - | |
| A2 | -7.3 | 2.26037 × 105 | (i) ARG-1004, LIG: O (ii) ARG-1004, LIG: O | VAL-1018, PRO-1016, LEU-1034, GLY-1011, PRO-1010 |
| A3 | -7.0 | 1.36190 × 105 | (i) ARG-1004, LIG:N (ii) i) ARG-1004, LIG:N | ASP-1020, LUE-1008 PRO-1010, VAL-1018 |
| A4 | -7.1 | 1.61246 × 105 | (i) ARG-1004, LIG:N (ii) ARG-1004, LIG:N | VAL-1018, LUE-1008, PRO-1010 |
| A5 | -7.1 | 1.61246 × 105 | (i) PRO-1004, LIG:H (ii) ARG-1004, LIG:N | VAL-1081, PRO-1016, ARG-1004 |
| A6 | -7.3 | 2.26037 × 105 | - | PRO-1016, VAL-1018, LEU-1034, GLY-1011, PRO-1010 |
| A7 | -7.5 | 3.16862 × 105 | ARG-1004, LIG:N | ASP-1020, ARG-1004, LEU-1008, PRO-1010, VAL-1018, LEU-1032 |
| A8 | -7.1 | 1.61246 × 105 | (i) ARG-1004, LIG:N (ii) ARG-1004, LIG:N (iii) GLN-1033 | LEU-1032, GLN-1032, VAL-1018, PRO-1010, LEU-1008, ARG-1004 |
| A9 | -7.3 | 2.26037 × 105 | (i) ARG-1004, LIG: N (ii) ARG-1004, LIG: N (iii) ARG-1004, LIG: N | ARG-1004, PRO-1016, ASP-1020 |
| A10 | -7.7 | 4.44181 × 105 | ARG-1004, LIG: N | VAL-1018, PRO-1010, LEU-1008, ARG-1004 |
| A11 | -7.3 | 2.26037 × 105 | ASP-1020, LIG:O (ii) ARG-1004, LIG:O | ASP-1020, ARG-1004 |
| A12 | -7.4 | 2.67624 × 105 | SER-1006, LIG:N (ii) ARG-1004, LIG:N | SER-1006, ARG-1004 |
| A13 | -7.3 | 2.26037 × 105 | - | PRO-1010, PRO-1016, VAL-1018, |
| A14 | -6.8 | 9.715 × 104 | (i)ASP-1020, LIG:H (ii) ARG-1004, LIG-O | ASP-1020, ARG-1004, VAL-1018, LEU-1008, PRO-1010 |
| A15 | -6.8 | 9.715 × 104 | (i) SER-1006, LIG:N (ii) ARG-1004, LIG:N (iii) ARG-1004, LIG:N | SER-1006, ARG-1004,ASP-1020, VAL-1018, LEU-1008, PRO-1010 |
| A16 | -7.3 | 2.26037 × 105 | (i) ARG-1004, LIG:N (ii) ARG-1004, LIG:N | ARG-1004, VAL-1018, LEU-1032 |
| A17 | -7.8 | 5.25902 × 105 | (i) ARG-1004, LIG:O (ii) ARG-1004, LIG:O | ARG-1004, VAL-1018, LEU-1034, PRO-1016 |
| A18 | -8.2 | 1.033440 × 106 | - | PRO-1010, PRO-1016, LEU-1034, VAL-1018, ARG-1004 |
| A19 | -7.5 | 3.16862 × 105 | (i) ARG-1004, LIG:N (ii) ARG-1004, LIG:N | ARG-1004, VAL-1018, ASP-1020, LEU-1032 |
| A20 | -7.8 | 5.25902 × 105 | ARG-1004, LIG:N | ASP-1020, ARG-1004, LEU-1008, PRO-1010, VAL-1018, LEU-1032 |
| A21 | -8.0 | 7.37217 × 105 | (i) ARG-1004, LIG:N (ii) ARG-1004, LIG:N | VAL-1018, ARG-1004, ASP-1020, LEU-1032, GLN-1033 |
| A22 | -8.4 | 1.448689 × 106 | (i) SER-1006, LIG:N (ii) ARG-1004, LIG: N | SER-1006, ARG-1004, PRO-1010, LEU-1008, VAL-1018, GLN-1033, LEU-1032 |
| A23 | -6.1 | 2.9788 × 104 | (i) PHE-1019, LIG:S (ii) ARG-1004, LIG:H (iii) ARG-1004, LIG:N | PHE-1019, ARG-1004, |
| A24 | -6.9 | 1.15027 × 105 | ||
| A25 | -6.6 | 6.9305 × 104 | (i) ARG-1004, LIG: N | ARG-1004, LEU-1008, PRO-1010 and VAL-1018 |
| A26 | -6.6 | 6.9305 × 104 | (i) ASN-1007, LIG:H (ii) SER-1006, LIG:N | PRO-1010, LEU-1008, ASN-1007, VAL-1018, SER-1006 and ARG-1004 |
| A27 | -6.4 | 4.9439 × 104 | (i) ARG-1004, LIG: N | VAL-1018, LEU-1032, ARG-1004, PRO-1010 and LEU-1008 |
| A28 | -6.9 | 1.15027 × 105 | (i) ARG-1004, LIG: N | ARG-1004, VAL-1018, PRO-1016, ASN-1007 and LEU-1032 |
| A29 | -7.3 | 2.26037 × 105 | (i) ARG-1004, LIG: N (ii) ARG-1004, LIG: N | LEU-1008, PRO-1010, ARG-1004, VAL-1018, and LEU-1032 |
| A30 | -6.6 | 6.9305 × 104 | (i) ARG-1004, LIG: N (ii) ARG-1004, LIG: N | LEU-1008, PRO-1010, VAL-1018, LEU-1032 and ARG-1004 |
| A31 | -7.6 | 3.75159 × 105 | (i) ARG-1004, LIG: N (ii) ARG-1004, LIG: N | LEU-1008, PRO-1010, VAL-1018, LEU-1032 and ARG-1004 |
| A32 | -7.7 | 4.44181 × 105 | (i) ARG-1004, LIG: N (ii) ARG-1004, LIG: N | PRO-1010, LEU-1008, VAL-1018, ARG-1004 and LEU-1032 |